La Jolla Pharmaceutical Company (NASDAQ: LJPC) is focused on improving and preserving human life through the development of novel pharmaceutical products. Riquent®, the company’s leading product in development, treats lupus renal disease, a leading cause of sickness and death in patients with lupus, by preventing or delaying renal flares. Additionally, La Jolla has developed small molecules designed to treat other autoimmune and inflammatory conditions. For further information, visit the Company’s web site at www.ljpc.com.
- 17 years ago
QualityStocks
La Jolla Pharmaceutical Company (NASDAQ: LJPC)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – BluSky AI Inc. (BSAI) Focused on Scalability in the Era of Artificial Intelligence
BluSky AI (OTC: BSAI) was featured in a recent article that discussed its strategic moves in…
-
QualityStocksNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Advancing Louisiana SMC to Play Pivotal Role in Critical Mineral Supply Chain
Disseminated on behalf of Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) and may include paid advertising.…
-
QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Releases New Datavault Insights Highlighting Execution, Growth and Global Momentum
Datavault AI (NASDAQ: DVLT) released a new Datavault Insights piece detailing the company’s ability to…